RNS Number:8940A
Lombard Medical Technologies PLC
04 April 2006



Lombard Medical enters research agreement with Amgen and University of Sheffield



London, UK, 4 April 2006 - Lombard Medical Technologies PLC is pleased to
announce that its Polymer Coatings Division has begun a research programme to
develop a new combination of drug and drug eluting polymer for the treatment of
coronary stent restenosis.

The project is to combine a proprietary drug from Amgen with Lombard Medical's
novel PEPTM drug eluting polymer and determine the elution profile on a drug
eluting stent in a 28-day model devised by the University of Sheffield. The
University of Sheffield has demonstrated the potential effectiveness of the drug
in the reduction of restenosis and earlier feasibility studies have shown the
drug is bioactive when it is released from the PEPTM polymer.

Stents are small expandable metal tubes that are implanted in arteries to keep
them open in patients whose vessels have become blocked due to coronary artery
disease, the most common cause of death in the Western World. These stents
sometimes become blocked again (restenosis), requiring a re-intervention
procedure to re-open them.

Drug-eluting stents represent a major innovative leap forward in the treatment
of coronary artery disease, in that the latest research findings indicate that
drug eluting stents reduce the need for re-intervention after stent implantation
to a greater extent than bare metal stents. Healthcare industry estimates have
suggested that the drug eluting stent market has reached a value of around $6bn.



Alistair Taylor, Executive Chairman of LMT, commented:



"We are very excited with this research collaboration between ourselves, Amgen
and the University of Sheffield. We believe there is a great opportunity to
license a second generation drug/polymer combination that is both safe and
effective to a coronary stent company."





Enquiries:



Lombard Medical Technologies PLC
Tel: 01235 750 800
Alistair Taylor, Executive Chairman
Brian Howlett, Chief Executive Officer



Financial Dynamics
Tel: 020 7831 3113
David Yates / John Gilbert



Notes to editors

Lombard Medical Technologies is a medical devices company developing stent
grafts and other medical products for use in the treatment of vascular disease.
The Company's lead product, AorfixTM, is a stent graft for the treatment of
aortic aneurysms, a balloon-like enlargement of the aorta which, if untreated,
may rupture and cause death.  Abdominal and thoracic aortic aneurysms are the
13th largest cause of death in the US and the market is estimated to be worth
approximately US$2 billion by 2010.  AorfixTM is currently being commercialised
in the EU, with US clinical trials expected to commence during 2006.  The
Company has a strategic collaboration with one of the world's leading medical
devices companies, Boston Scientific.

Lombard Medical has recently successfully completed its initial public offering
on AIM and was admitted to listing in December 2005, raising #23.9 million, net
of expenses.  The Company, based in Oxfordshire & Yorkshire, currently employs
56 people.

Further background on the Company can be found at www.lombardmedical.com.






                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

AGRAKNKBABKDQQK
Lombard Medical Technologies (LSE:LMT)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Lombard Medical Technologies Charts.
Lombard Medical Technologies (LSE:LMT)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Lombard Medical Technologies Charts.